Salethamide

Salethamide

SCHEMBL588724

CCN(CC)CCNC(=O)c1ccccc1O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.71
KDM4E B2RXH2 2/20 0.71
HPGD P15428 2/20 0.71
NAAA Q02083 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.56
TSHR P16473 3/20 0.54
LMNA P02545 2/20 0.54
HTT P42858 2/20 0.54
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54
NLRP1 Q9C000 1/20 0.54
SLC22A2 O15244 1/20 0.54
SLC22A1 O15245 1/20 0.54
ACHE P22303 1/20 0.54
MAPK1 P28482 1/20 0.54
CYP2C19 P33261 1/20 0.54
APP P05067 3/20 0.53
BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salethamide SCHEMBL11573255 0.98 ALDH1A1 (0.69) ALDH1A1KDM4EHPGDNAAASMN1; SMN2
Salethamide SCHEMBL126228 0.92 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDNAAASMN1; SMN2
Salethamide SCHEMBL29658191 0.92 ALDH1A1 (0.61) ALDH1A1KDM4EHPGDNAAASMN1; SMN2
SCHEMBL8640837 0.91 NAAA (0.67) ALDH1A1KDM4EHPGDNAAATSHR
SCHEMBL14035537 0.90 HTT (0.59) ALDH1A1KDM4EHPGDNAAASMN1; SMN2
SCHEMBL24503506 0.84 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2TSHR
SCHEMBL12447795 0.84 HPGD (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2TSHR
SCHEMBL14868417 0.84 NAAA (0.58) ALDH1A1KDM4EHPGDNAAASMN1; SMN2
SCHEMBL8639778 0.84 NAAA (0.60) ALDH1A1KDM4EHPGDNAAASMN1; SMN2
SCHEMBL14872241 0.84 NAAA (0.54) ALDH1A1KDM4EHPGDNAAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377779-B2 Carbonate prodrugs and methods of using the same ACORDA THERAPEUTICS, INC. (US) 2019-08-13 US claimed
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. 2018-03-29 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20110212927-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. (US) 2011-09-01 US claimed
CN-102149282-A Carbonate prodrugs and methods of using the same NEUROGESX INC 2011-08-10 CN claimed
EP-2291084-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME Neurogesx, Inc. (US) 2011-03-09 EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
WO-2009143297-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. (US) 2009-11-26 WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-12102653-B2 Ligand regulated protein-protein interaction system ST. ANNA KINDERKREBSFORSCHUNG (AT) 2024-10-01 US disclosed
US-20240000841-A1 LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM ST ANNA KINDERKREBSFORSCHUNG (AT) 2024-01-04 US disclosed
US-5001115-A Prodrugs of biologically active hydroxyaromatic compounds UNIVERSITY OF FLORIDA (US) 1991-03-19 US disclosed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP disclosed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212927-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 ALDH1A1 1014/4885KDM4E 1604/4885HPGD 238/4885
US-10377779-B2 Carbonate prodrugs and methods of using the same CA6, CA7, CA4 ALDH1A1 1014/4885KDM4E 1604/4885HPGD 238/4885
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 ALDH1A1 1014/4885KDM4E 1604/4885HPGD 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.